Yousif Capital Management LLC Takes Position in Fresenius Medical Care AG (NYSE:FMS)

Yousif Capital Management LLC bought a new position in shares of Fresenius Medical Care AG (NYSE:FMS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,179 shares of the company’s stock, valued at approximately $208,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Verition Fund Management LLC purchased a new stake in Fresenius Medical Care in the 3rd quarter valued at about $237,000. JPMorgan Chase & Co. lifted its stake in Fresenius Medical Care by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock worth $211,000 after purchasing an additional 1,528 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Fresenius Medical Care by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after buying an additional 2,233 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Finally, MML Investors Services LLC lifted its holdings in shares of Fresenius Medical Care by 5.3% during the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after acquiring an additional 753 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Down 3.3 %

FMS stock opened at $23.46 on Tuesday. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.25. The business has a fifty day moving average price of $23.46 and a 200-day moving average price of $21.54. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The stock has a market capitalization of $13.76 billion, a P/E ratio of 19.38, a P/E/G ratio of 0.80 and a beta of 0.93.

Analyst Upgrades and Downgrades

A number of brokerages have commented on FMS. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.